Prevention cardiovasculaire chez la personne agee

[en] The aging of the cardiovascular system leads to an increased incidence of hypertension, coronary artery disease and ischemic stroke. Since cardiovascular disease is the leading cause of morbidity and mortality in patients > or = 70 years old, prevention seems crucial for improving quality of life and reducing medical costs. In this article we present some aspects of cardiovascular prevention in elderly patients.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Lebois, Florence ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie

Allepaerts, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Gériatrie

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Pierard, Luc ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Language :

French

Title :

Prevention cardiovasculaire chez la personne agee

Alternative titles :

[en] Prevention of Cardiovascular Disease in the Elderly

Publication date :

May 2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

275-8

Peer reviewed :

Peer reviewed

Available on ORBi :

since 24 June 2013

Statistics

Number of views

135 (5 by ULiège)

Number of downloads

38 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

SHEP Cooperative Research Group. - Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 1991, 265, 3255-3264.
Dahlöf B, Lindholm LH, Hansson L, et al. - Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338, 1281-1285.
Staessen JA, Fagard R, Thijs L, et al. - Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997, 350, 757-764.
Cutler JA, MacMahon SW, Furberg CD. - Controlled clinicals trials of drug treatment for hypertension: a review. Hypertension, 1989, 13, 136-144.
Psaty BM, Smith NL, Siscovick DS, et al. - Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA, 1997, 277, 739-745.
Pollare T, Lithell H, Berne C. - A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med, 1989, 321, 868-873.
Lonn EM, Yusuf S, Jha P, et al. - Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation, 1994, 90, 2056-2069.
Staessen JA, Fagard R, Thijs L, et al (for the Systolic Hypertension in Europe-SYST-EUR-trials investigators). - Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997, 350, 757-764.
Yusuf S, Sleight P, Pogue J, et al. - Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342, 145-153.
Scheen AJ. - L'étude HOPE: démonstration de la protection cardio-vasculaire du ramipril, un inhibiteur de l'enzyme de conversion de l'angiotensine. Rev Med Liège, 1999, 54, 835-836.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. - Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA, 2002, 288, 2981-2997.
Scheen AJ, Krzesinski, JM. - L'étude clinique du mois. Quel antihypertenseur en première intention? Résultats de l'étude ALLHAT. Rev Med Liège, 2003, 58, 47-52.
Hansson L, Hedner T, Lund-Johansen P, et al. - Randomised trial of effects of calcium antagonists compared with diuretics and B-blockers on cardiovascular morbidity and mortality in hypertension. From the Nordic Diltiazem Study. Lancet, 2000, 356, 359-365.
Hansson L, Lindholm LH, Ekbom T, et al. - Randomised trial of old new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 1999, 354, 1751-1755.
Lindon MH, Wing MB, Christopher M, et al. - A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med, 2003, 348, 583-592.
Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE Study Group. - Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
Lindholm LH, Ibsen H, Dahlöf B, et al, for the LIFE Study Group. - Cardiovascular morbidity and mortality in patients with diabetes in Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 1004-1010.
Chen Z, Peto R, Collins R, et al. - Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ, 1991; 303, 276-282.
Szatrowski TP, Peterson AV, Shimizu Y, et al. - Serum cholesterol, other risk factors, and cardiovascular disease in a Japonese cohort. J Chron Dis, 1984, 7, 569-584.
Scandinavian Simvastatin Survival Study Group. - Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. - Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998, 339, 1349-1357.
Shepherd J, Blauw GJ, Murphy MB, et al., on behalf of the PROSPER Study Group. - The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol, 1999, 84, 1192-1197.
Shepherd J, Blauw GJ, Murphy MB, et al., on behalf of the PROSPER Study Group. - Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002, 360, 1623-1630.
Heart Protection Study Collaborative Group MRC/BHF. - Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-23.
Kulbertus H, Scheen AJ. - L'étude clinique du mois. La MRC/BHF Heart Protection Study. Rev Med Liège, 2002, 57, 613-616.
Marchioli R, Schweiger C, Levantesi G, et al. - Antioxidant Vitamins and Prevention of Cardiovascular Disease: Epidemiological and Clinical Trial Data. Lipids, 2001, 36, S53-S63.
Heart Protection Study Collaborative Group MRC/BHF. - Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 23-33.
The Heart Outcomes Prevention Evaluation Study Investigators. - Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med, 2000, 342, 154-160.
Grodstein F, Manson JE, Stampfer MJ. - Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med, 2001, 135, 1-8.
Hulley S, Grady D, Bush T, et al. - Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998, 280, 605-613.
Viscoli CM, Brass LM, Kernan WN, et al. - A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med, 2001, 345, 1243-1249.